J.P. Morgan Securities: Maintaining the BioCryst Pharma (BCRX.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $14.00 to $15.00.
摩根大通证券公司：维持BioCryst Pharma(BCRX.US)评级，由优于大市调整至优于大市评级, 目标价由14.00美元调整至15.00美元。
J.P. Morgan Securities: Maintaining the BioCryst Pharma (BCRX.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $14.00 to $15.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated